Sleep Disorders In Anti-NMDAR Encephalitis (1605)

摘要: Objective: To describe the sleep disorders in anti-NMDA receptor encephalitis (anti-NMDARe) Background: Patients with anti-NMDARe often have problems. The severity and complexity of accompanying neuropsychiatric symptoms, mask these disorders, complicate their assessment, explain lack prior studies Design/Methods: recovering from were invited to participate a prospective observational single center study including comprehensive clinical, video-polysomnography (V-PSG) assessment neuropsychological evaluation. Age sex-matched healthy participants served as controls Results: Eighteen patients (89% female, median age 26 years, IQR 21–29) 21 (81% 23 18–26) included. In acute stage, 16 (89%) reported insomnia 2 hypersomnia (1 rapidly changed insomnia). After 14 (78%) had hypersomnia. At study-admission (median 183 days after disease-onset, 110–242) 8 still hypersomnia, 1 insomnia, 9 normal duration. more daytime sleepiness than (higher Barcelona Sleepiness Index, p=0.02, Epworth Score, p=0.04), but similar perception quality. On V-PSG, efficiency was both groups although frequently multiple longer confusional arousals NREM (p=0.03). Additionally, 13 (72%) cognitive deficits, 12 (67%) psychological, social, or occupational disability, 33% depression mania. Between disease-onset last follow-up, developed hyperphagia, 6 (33%) hypersexuality (2 requiring hospitalization), all associated dysfunction. study-admission, higher body mass index compared (median, IQR: 23.5, 22.3–30.2 vs. 20.5, 19.1–21.1; p=0.007) Conclusions: Sleep disturbances are frequent anti-NMDARe. They show temporal pattern (predominantly at onset; during recovery), associate behavioral changes, can occur sleep. Disclosure: Dr. Arino has nothing disclose. Munoz-Lopetegi Martinez-Hernandez Armangue received research support Mutua Madrilena Foundation. Santamaria Dalmau personal compensation an editorial capacity for Editor: Neurology, Neuroimmunology, Neuroinflammation; UpToDate. royalty, license fees, contractual rights payments Euroimmune. Sage therapeutics.